Recently, small-molecule inhibitors of the MLL–Menin interaction MI-463 and MI-503 were developed, and they were used to demonstrate that pharmacologic inhibition of the MLL–Menin interaction blocks progression of MLL leukemia in vivo without impairing normal hematopoiesis (54). The gene discussed is KMT2A; the disease is leukemia.